Evidence map›Paper›PMID 40926222›Full record

ArticleBMC pulmonary medicine2025

Prolonged in vitro anti-bacterial, anti-inflammatory, and surfactant-promoting effects of volatile anesthetics.

Claudia Scheffzük, Johanna Lührmann, Robin Brinkmann, Dominika Biedziak, Kristina Gloystein, Patrick Kellner, Cordula Stamme

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claudia Scheffzük *Division of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany. claudia.scheffzuek@ruhr-uni-bochum.de.ORCID http://orcid.org/0000-0002-9412-843X
Johanna Lührmann *Division of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.
Robin BrinkmannDivision of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.
Dominika BiedziakDivision of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.
Kristina GloysteinDivision of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.
Patrick Kellner *Division of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.
Cordula Stamme *Division of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVolatile anesthetics are gaining recognition for their benefits in long-term sedation of mechanically ventilated patients with bacterial pneumonia and acute respiratory distress syndrome. In addition to their sedative role, they also exhibit anti-bacterial and anti-inflammatory properties, though the mechanisms behind these effects remain only partially understood. In vitro studies examining the prolonged impact of volatile anesthetics on bacterial growth, inflammatory cytokine response, and surfactant proteins - key to maintaining lung homeostasis - are still lacking.

methodsUsing an anaerobic chamber setup, we evaluated the effects of the most commonly used volatile anesthetics, Sevoflurane and Desflurane, at clinically relevant concentrations on the growth of Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus. Bacterial growth was monitored over 24 h, assessing OD

resultsSevoflurane and Desflurane significantly reduced Pseudomonas aeruginosa growth as expressed consistently in OD

conclusionsProlonged anti-bacterial and anti-inflammatory effects of Sevoflurane and Desflurane include both the reduction of Pseudomonas aeruginosa and Staphylococcus aureus growth as well as the inhibition of LPS-induced chemokine release by A549 epithelial cells paralleled by an increase of surfactant protein expression. These effects highlight the potential of volatile anesthetics beyond sedation in supporting lung function in ventilated patients with respiratory failure.

Indexed as

Anesthetics, InhalationAnti-Bacterial AgentsAnti-Inflammatory AgentsIsofluraneA549 CellsDesfluraneEscherichia coliHumansInterleukin-8LipopolysaccharidesPseudomonas aeruginosaSevofluraneStaphylococcus aureusAnesthetics, InhalationAnti-Bacterial AgentsAnti-Inflammatory AgentsDesfluraneInterleukin-8IsofluraneLipopolysaccharidesSevofluraneA549 cellsARDSCytokinesDesfluraneIL-8PneumoniaPseudomonas aeruginosaSevofluraneSurfactant proteinVolatile anesthetics

Identifiers

PMID40926222
PMCPMC12421742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.